List of Excipients in Branded Drug HORIZANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	HORIZANT	gabapentin enacarbil	53451-0103	DIBASIC CALCIUM PHOSPHATE DIHYDRATE	2026-11-10
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	HORIZANT	gabapentin enacarbil	53451-0103	GLYCERYL DIBEHENATE	2026-11-10
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	HORIZANT	gabapentin enacarbil	53451-0103	MAGNESIUM STEARATE	2026-11-10
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	HORIZANT	gabapentin enacarbil	53451-0103	SILICON DIOXIDE	2026-11-10
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	HORIZANT	gabapentin enacarbil	53451-0103	SODIUM LAURYL SULFATE	2026-11-10
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	HORIZANT	gabapentin enacarbil	53451-0103	TALC	2026-11-10

Horizant Excipient Strategy and Commercial Opportunities for Gabapentin Enacarbil

Last updated: August 26, 2026

Horizant, the branded formulation of gabapentin enacarbil, has commercial opportunity in differentiated oral delivery, excipient optimization, generic formulation development, and lifecycle products. The strongest technical constraint is the prodrug’s dependence on intestinal absorption mechanisms, dose proportionality, food effects, and controlled release. Excipient changes that alter gastrointestinal transit, dissolution, or transporter exposure can affect bioequivalence and clinical performance.

The most attractive opportunities are lactose-free reformulation, lower-pill-burden dosage forms, patient-friendly modified-release products, and manufacturing platforms that improve tablet robustness without changing the release profile. A direct generic strategy remains legally sensitive because the product’s commercial protection has historically depended on formulation, method-of-use, and prodrug-related patent claims rather than on a simple active-ingredient composition claim.

What is Horizant and how does its formulation work?

Horizant contains gabapentin enacarbil, a prodrug of gabapentin. The FDA approved Horizant extended-release tablets in 2011 for moderate-to-severe primary restless legs syndrome and in 2012 for postherpetic neuralgia.[1]

Gabapentin enacarbil is designed to improve the oral absorption characteristics of gabapentin. After absorption, it is converted to gabapentin by nonspecific esterases. The formulation is not intended to be substituted on a milligram-for-milligram basis with immediate-release gabapentin.

Product attribute	Horizant profile
Active ingredient	Gabapentin enacarbil
Dosage form	Extended-release tablet
Commercial strengths	300 mg and 600 mg
Main indications	Restless legs syndrome; postherpetic neuralgia
Administration	With food
Release design	Extended release
Primary commercial issue	Maintaining exposure while managing food effect, tolerability, and tablet burden
FDA application	NDA 022399
Regulatory pathway	505(b)(1) new drug application

The 600-mg tablet is generally used for restless legs syndrome, while postherpetic neuralgia treatment can require twice-daily administration. The label warns against crushing, chewing, or breaking the tablets because those actions can alter extended release.[1]

What excipients are used in Horizant tablets?

The Horizant formulation uses standard oral solid-dose excipients for tablet structure, granulation, lubrication, and film coating. Public labeling identifies excipient classes including lactose monohydrate, microcrystalline cellulose, copovidone, crospovidone, magnesium stearate, and film-coating components such as polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol, and iron oxide colorants.[1,2]

The exact commercial value of each excipient depends on its functional role rather than its presence alone.

Excipient or excipient class	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Creates a lactose-free reformulation opportunity
Microcrystalline cellulose	Diluent, binder, tablet-strength contributor	Useful for hardness and manufacturability
Copovidone	Binder and granulation aid	Supports tablet integrity and content uniformity
Crospovidone	Disintegrant	Requires careful control in an extended-release product
Magnesium stearate	Lubricant	Excessive use can slow wetting and dissolution
Polyvinyl alcohol	Film former	Can support coating durability
Talc	Anti-tacking and coating aid	Relevant to coating process stability
Titanium dioxide and iron oxides	Opacifying and coloring agents	Replaceable for market-specific or clean-label positioning
Polyethylene glycol	Plasticizer in film coating	Affects coating flexibility and process performance

The critical point is that Horizant is an extended-release product. A formulation that improves disintegration may undermine controlled release. Conversely, excessive hydrophobic lubrication, high binder levels, or a dense tablet matrix may delay drug release and reduce bioavailability.

Which excipient strategies have the highest commercial potential?

Lactose-free Horizant or generic-equivalent tablets

Lactose is the clearest excipient-based differentiation opportunity. A lactose-free tablet could target patients with lactose intolerance, reduce procurement restrictions for hospitals and specialty pharmacies, and create a formulation distinction for a 505(b)(2) product or authorized-generic strategy.

Potential substitutes include:

• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Spray-dried cellulose systems
• Coprocessed excipient platforms
• Low-moisture, directly compressible polyols

The replacement must preserve tablet density, coating performance, dissolution, and pharmacokinetics. Mannitol is commercially attractive because it can provide a clean-label position and favorable mouthfeel, but it may require changes in compression force and lubricant optimization.

Lower-pill-burden dosage forms

Postherpetic neuralgia treatment may require twice-daily dosing. A higher-strength tablet, once-daily tablet, or alternate modified-release profile could reduce pill burden. The opportunity is technically difficult because a higher dose may increase tablet size, alter dose proportionality, and create a different exposure profile.

A viable development target would be a 900-mg or 1,200-mg once-daily product only if the pharmacokinetic profile remains within the therapeutic range and the tablet can be manufactured at an acceptable size. Such a product would likely require new clinical or bridging studies and could face method-of-use and formulation patent scrutiny.

Patient-friendly dosage forms

Horizant is an extended-release tablet and cannot be crushed or chewed. Commercial opportunities include:

• Smaller tablets with equivalent dose
• Sprinkle capsules containing controlled-release multiparticulates
• Swallowing-friendly coated minitablets
• Orally dispersible products that preserve extended release
• Packaged titration systems
• Dose-specific blister configurations

A sprinkle product is potentially more valuable than a conventional tablet reformulation because it addresses dysphagia and geriatric adherence. It also creates a larger formulation barrier than simply changing a diluent. The key technical requirement is that the multiparticulate system must resist premature release after administration with soft food or liquid.

How do excipients affect gabapentin enacarbil absorption?

Gabapentin enacarbil absorption is more complex than passive dissolution and diffusion. The prodrug uses intestinal transport pathways, including the monocarboxylate transporter 1 pathway, to improve uptake.[3]

Excipients can influence the product through several mechanisms:

1. Dissolution timing. A faster or slower release profile changes the concentration available for intestinal uptake.
2. Gastrointestinal transit. Osmotic excipients and certain polyols can alter transit and exposure.
3. Local pH and microenvironment. Buffering agents may affect prodrug stability and dissolution.
4. Food interaction. The product is administered with food, so excipient changes that alter fed-state dissolution can produce clinically relevant differences.
5. Tablet erosion. Hydrophilic polymers and coating systems can change the release mechanism.
6. Moisture sensitivity. Water uptake may affect granule strength, degradation, and dissolution.
7. Transporter competition. Excipients or formulation components that influence intestinal transporter activity require specific evaluation.

The development target should not be maximum dissolution. It should be reproducible exposure under the labeled fed condition, with a robust in vitro-in vivo relationship.

What formulations are protected by Horizant-related intellectual property?

The relevant intellectual-property categories are broader than the tablet composition:

IP category	Potential claim scope	Competitive effect
Gabapentin enacarbil composition	Prodrug structure, stereochemistry, or salt form	Core barrier, subject to expiry and claim validity
Extended-release formulation	Release profile, matrix, coating, or dosage form	Directly relevant to generic tablet design
Method of treatment	Restless legs syndrome or postherpetic neuralgia dosing	Can constrain labeled generic use
Pharmacokinetic profile	Exposure parameters or food-conditioned administration	May support formulation-specific claims
Manufacturing process	Granulation, coating, particle engineering, or conversion	Can block process replication
Combination or packaging claims	Dose titration or treatment regimen	Often lower-value but commercially relevant

A patent analyst should separate the original composition and method patents from later formulation patents. Patent expiry can differ materially by family because of continuation practice, patent term adjustment, terminal disclaimers, and statutory patent-term extension.

The FDA Orange Book is the controlling commercial reference for listed patents associated with NDA 022399. The product’s regulatory exclusivity and patent protection are separate concepts. FDA exclusivity can expire before listed patents, and patent expiry does not itself guarantee immediate generic launch if other listed claims remain operative.[4]

When did Horizant lose regulatory exclusivity?

Horizant’s initial FDA approval occurred in 2011. The product’s five-year new chemical entity exclusivity period would have run from the approval date, subject to the FDA’s regulatory classification of the active moiety and applicable exclusivity rules. That period did not eliminate later patent-based barriers.

The post-exclusivity market analysis should therefore use three dates:

Timing question	Business significance
FDA approval date	Starts regulatory exclusivity and patent-term calculations
Regulatory exclusivity expiry	Determines when an ANDA or 505(b)(2) filing may be submitted
Latest enforceable listed-patent expiry	Determines practical generic launch risk

For Horizant, the commercial question is not whether regulatory exclusivity has ended. It has. The relevant question is whether a generic applicant can obtain approval with a Paragraph IV certification, a section viii carve-out, or a later filing strategy that avoids remaining patent claims.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval for gabapentin enacarbil extended-release tablets must address the reference product’s listed patents through the ANDA certification process. Possible strategies include:

• Paragraph III certification with launch after patent expiry
• Paragraph IV certification asserting invalidity, unenforceability, or non-infringement
• Section viii statement omitting a patented indication
• Formulation design that avoids asserted release or excipient claims
• 505(b)(2) development using a differentiated dosage form

A Paragraph IV notice can trigger a 30-month stay under the Hatch-Waxman framework if the NDA holder or patent owner files an infringement action within the statutory period.[5] The commercial risk depends on the scope of the asserted claims, the number of patents, the litigation venue, and whether the generic product design creates a credible non-infringement position.

A label carve-out may be difficult if the patented indication is central to the product’s commercial value. Restless legs syndrome is a narrower indication than postherpetic neuralgia, but a generic applicant may seek to omit one indication if the remaining label supports commercial viability.

What is the Orange Book status of Horizant?

Horizant is listed in the FDA Orange Book under NDA 022399. Orange Book review should cover:

• Active listed patents
• Patent use codes
• Patent delisting activity
• Pediatric exclusivity, if applicable
• Approved strengths and dosage form
• Generic applicants and tentative approvals
• Any litigation-linked 30-month stays

Orange Book listings do not provide a complete freedom-to-operate analysis. They do not capture every manufacturing patent, formulation patent, foreign patent, trade secret, or non-listed process right. A generic developer must pair Orange Book review with USPTO family analysis, prosecution history, and Federal Circuit claim-construction precedent.

How strong is the Horizant patent estate?

The estate is strongest where claims connect the prodrug to a defined extended-release profile, fed-state administration, or disease-specific dosing regimen. A basic excipient substitution is more likely to avoid a narrow composition claim than a formulation that reproduces the same dissolution mechanism and pharmacokinetic profile.

Patent-strength factors include:

• Claim breadth covering multiple excipient classes
• Written-description support for alternative release systems
• Continuation and divisional activity
• Patent-term adjustment
• Prosecution amendments narrowing release or dosing claims
• Prior-art exposure from gabapentin and other prodrugs
• Enablement of high-dose, once-daily products
• Whether method claims cover all commercially practical dosing regimens

A generic strategy based only on replacing lactose with mannitol may have limited value if the remaining product still practices broad extended-release claims. A full design-around would need to evaluate release mechanism, tablet architecture, manufacturing process, and labeling.

Which companies have commercial opportunities around Horizant?

The opportunity set includes several business models.

Generic manufacturers

Generic companies can pursue an ANDA for the existing 300-mg and 600-mg extended-release tablets. The primary value drivers are patent timing, bioequivalence feasibility, manufacturing cost, and the size of the remaining branded market.

505(b)(2) developers

A 505(b)(2) applicant could pursue:

• A lactose-free version
• A sprinkle or multiparticulate product
• A new strength
• A modified dosing schedule
• A dysphagia-oriented presentation
• A formulation with improved fed-state tolerability

This route may support three-year exclusivity for certain new clinical investigations, but it does not automatically avoid patent infringement.

Excipient suppliers

Suppliers can target:

• Direct-compression lactose alternatives
• Low-moisture binders
• Controlled-release polymer systems
• Coating platforms with lower titanium dioxide or talc content
• Coprocessed excipients that improve tablet hardness at lower compression force
• Multiparticulate coating systems

The supplier opportunity is strongest where the excipient solves a measurable manufacturing problem, such as sticking, capping, friability, dissolution variability, or scale-up yield.

Brand lifecycle managers

The brand owner can extend commercial differentiation through:

• Patient-support packaging
• Higher-strength dosing
• Sprinkle delivery
• Specialty-pharmacy adherence programs
• Indication-specific packaging
• Geographic licensing
• Authorized generic supply

How does Horizant compare with gabapentin and pregabalin?

Product	Active ingredient	Release profile	Key commercial distinction
Horizant	Gabapentin enacarbil	Extended release	Prodrug-based absorption and branded indication positioning
Immediate-release gabapentin	Gabapentin	Immediate release	Low-cost generic, higher dosing frequency
Gralise	Gabapentin	Extended release	Alternative extended-release gabapentin platform
Lyrica and generic pregabalin	Pregabalin	Immediate or controlled formulations	Strong generic competition and broad clinical use

Horizant’s commercial advantage is not simply the gabapentin pharmacology. It is the combination of prodrug design, extended release, food-conditioned administration, and approved indications. Its disadvantage is a higher formulation and regulatory burden than immediate-release gabapentin.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers include uniform distribution of a relatively high drug load, control of granulation moisture, tablet coating consistency, and maintenance of dissolution across scale. Extended-release products also require tighter process controls because small changes in lubricant concentration, compression force, coating weight, or particle size can shift exposure.

The highest-value manufacturing know-how may be protected as trade secrets rather than patents. This can affect technology-transfer negotiations even after patent expiry. Contract manufacturers with experience in controlled-release tablets and multiparticulate coating have a competitive advantage.

Geographic coverage also matters. U.S. Orange Book patents do not determine entry in Europe, Canada, Japan, or emerging markets. Each jurisdiction requires separate analysis of patent term, supplementary protection certificates, regulatory exclusivity, and local product approvals.

Key Takeaways

• Horizant is an extended-release gabapentin enacarbil product with 300-mg and 600-mg tablets.
• Lactose replacement is the most straightforward excipient-led differentiation opportunity.
• Sprinkle multiparticulates, smaller tablets, and lower-pill-burden products offer higher commercial value but require more extensive development.
• Excipient changes must be evaluated against transporter-mediated absorption, fed-state administration, dissolution, and pharmacokinetics.
• FDA regulatory exclusivity has expired, but patent-based generic entry remains a separate analysis.
• Orange Book patents, method-of-use claims, formulation claims, manufacturing patents, and trade secrets should be reviewed together.
• Generic ANDA, Paragraph IV, section viii, and 505(b)(2) strategies each present different timing and litigation risks.
• The strongest commercial opportunity is a differentiated product that improves administration or tolerability without reproducing the reference product’s protected release architecture.

FAQs About Horizant Excipient and Commercial Strategy

Can Horizant be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, cellulose, starch, or calcium phosphate systems, but the reformulation must preserve extended release, fed-state exposure, tablet strength, and bioequivalence.

Is a lactose-free Horizant eligible for 505(b)(2) approval?

Potentially. A lactose-free formulation could qualify for a 505(b)(2) application if it relies partly on the reference product’s safety and efficacy findings while requiring new studies to support the formulation change.

Can gabapentin enacarbil be marketed as an immediate-release tablet?

An immediate-release gabapentin enacarbil product would be a materially different product. It would require separate development and would not automatically rely on Horizant’s extended-release approval.

Does replacing an excipient avoid Horizant patent infringement?

No. Replacing lactose may avoid a narrow composition claim, but infringement can still arise from broader formulation, release-profile, method-of-use, process, or pharmacokinetic claims.

What is the highest-value lifecycle product for Horizant?

A patient-friendly controlled-release multiparticulate product, particularly a sprinkle presentation that reduces swallowing difficulty while preserving exposure, is likely to offer more commercial differentiation than a simple excipient substitution.

References

1. U.S. Food and Drug Administration. (2023). Horizant (gabapentin enacarbil) extended-release tablets: Prescribing information.
2. National Library of Medicine. (2024). DailyMed: Horizant, gabapentin enacarbil extended-release tablets.
3. Cundy, K. C., Anjaneyulu, K., Cao, A., et al. (2008). Once-daily gabapentin enacarbil: Pharmacokinetics, safety, and tolerability in healthy subjects. Journal of Clinical Pharmacology, 48(12), 1378-1388.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Code, 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.